Stay updated with breaking news from Yuqin song. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Golidocitinib can produce lasting responses in patients with relapsed or refractory PTCL, according to a new study. Golidocitinib can produce lasting responses in patients with relapsed or refractory PTCL, according to a new study. ....
DZD8586 showcased antitumor activity and favorable safety with limited grade 3 or greater treatment-emergent adverse effects in patients with heavily pretreated B-cell non-Hodgkin lymphoma, according to preliminary findings from a pooled analysis of two ongoing phase 1 trials. ....
Golidocitinib displayed antitumor activity and an acceptable safety profile in patients with refractory/relapsed peripheral T-cell lymphoma, according to data from the pivotal phase 2 JACKPOT8 study. ....
Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting - read this article along with other careers information, tips and advice on BioSpace ....
Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting ....